CollPlant Biotechnologies Ltd - ADR

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant's regenerative breast implants Readying breast implant study in large animals for initiation by year end    Continued positive sales trajectory for 3D bioinks Cash and cash equivalents totaled $22.3 million as of June 30, 2023; cash runway extended with additional $10 million milestone payment received in July 2023 from AbbVie Revenues of $10.6 million and operating income of $5.7 million for the first six months of 2023 Conference call to be held on August 24, 2023 at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , Aug. 24, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs. "This quarter, we were very pleased to announce the achievement of an important milestone related to the dermal filler product developed in collaboration with our partner, AbbVie, for which we received a $10 million payment.

CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million

-  Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

REHOVOT, Israel , June 26, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced the achievement of a milestone with respect to the clinical phase dermal filler product, according to its agreement with AbbVie for the development of a regenerative dermal and soft tissue filler product. According to the agreement, the achievement of this milestone triggers a $10 million payment from AbbVie to CollPlant.

CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q1 2023 Earnings Conference Call May 24, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C.

CollPlant Biotechnologies Ltd. (CLGN) Q1 2023 Earnings Call Transcript

Strong positive sales trajectory for rhCollagen based products Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human Collagen   Readying sites to begin large-animal study planned in the second half of 2023 to advance 3D bioprinted regenerative breast implant program Conference call to be held on May 24, 2023 at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , May 24, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update on its programs. "Recently, we announced a collaborative agreement with Stratasys, a world-leader in 3D printing as well as completed the first large-animal study for our 3D bioprinted regenerative breast implants," said CollPlant's Chief Executive Officer, Yehiel Tal.

CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update

-  Conference call to be held on May 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 2, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the first quarter of 2023 on May 24, 2023, before the market open.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Stratasys

EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)---- $SSYS #3dprinting--Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys' P3 technology-based bioprinter and CollPlant's rh-Collagen-based bioinks.

Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C.

CollPlant Biotechnologies Ltd. (CLGN) Q4 2022 Earnings Call Transcript

Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen Additional large-animal study planned in H2 2023 to further 3D bioprinted regenerative breast implant program Conference call to be held on March 29, 2023 at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , March 29, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2022 and provided a corporate update on its programs. Yehiel Tal, CollPlant's Chief Executive Officer, stated, "We remain highly focused on becoming a global leader in regenerative medicine with our pioneering collagen-based platform to help people live longer and better.

Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update

- Conference call to be held on March 29, 2023 at 10:00 am U.S. EDT - REHOVOT, Israel , March 14, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the full year ended December 31, 2022, on March 29, 2023, before the market open.  The Company will then host a conference call and webcast to discuss its financial results along with corporate updates on March 29th at 10:00 am Eastern Time.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Possesses only plant-based collagen product with multiple end-market opportunities. AbbVie relationship alone justifies the current valuation.

CollPlant: Expanding End-Market Opportunities

Study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants No indication of adverse reaction was noted Promising results support continued development of rhCollagen-based regenerative breast implants as a revolutionary and potentially safer and more natural alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients rhCollagen-based regenerative breast implants address $2.5 billion global breast implant market REHOVOT, Israel , Jan. 4, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced that it has successfully completed a large animal study for its recombinant human collagen (rhCollagen)-based 3D bioprinted regenerative breast implants, addressing the $2.5 billion global breast implant market. Supported by these promising results, the Company is planning to initiate a follow-up large animal study during 2023 using commercial-size implants to support subsequent human studies and future product commercialization.

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applications Collink.3D™ 50L strengthens CollPlant's platform of bioink solutions to biopharma and academic customers seeking animal-free alternatives with improved bio-functionality, safety and reproducibility  REHOVOT, Israel , Jan. 3, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs. Collink.3DTM 50L, the result of a comprehensive development effort, is a tunable bioink that can be easily reconstituted to form solutions with application-specific concentrations, formulated with other components and crosslinked to form hydrogels that meet the demand for specific geometric, physical and biological properties of different 3D constructs.

CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv University and SHEBA Hospital 3D bioprinted regenerative breast implant program on track for Q1 2023 readout of large animal study Bioink platform expanded with recent launch of Collink.3D™ 90 to offer additional functionality and performance benefits of biofabricated constructs Strong balance sheet with cash and cash equivalents of $33M as of September 30, 2022 REHOVOT, Israel , Dec. 1, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2022 and provided an update on the Company's business developments. "CollPlant made significant progress this quarter with our development partners to advance and diversify our product portfolio, which is targeting large commercial opportunities in both existing and new markets, including medical aesthetics and personalized medicine," said Yehiel Tal, CollPlant's CEO.

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results

Agreement to accelerate development of a 'Gut-on-a-Chip' tissue model to improve therapeutic choice and outcome of ulcerative colitis patients CollPlant to fund development and receive exclusive license to manufacture and commercialize human intestine tissue model Intestine model highlights vast application possibilities for rhCollagen and CollPlant's strategic expansion into personalized medicine, an emerging approach for disease treatment REHOVOT, Israel , Nov. 15, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products, together with Ramot, the Technology Transfer Company of Tel Aviv University and Sheba Medical Center, a hospital ranked by Newsweek magazine as one of the Top 10 world best hospitals for the 4th consecutive year (2019-2022), today announced entering into a license and research agreement to co-develop a 'Gut-on-a-Chip' tissue model for drug discovery and high throughput screening of drugs. The model is intended to be used in personal medicine applications for the treatment of ulcerative colitis, an inflammatory bowel disease affecting millions of individuals worldwide.

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Collink.3D™ 90 offers additional functionality to address wide range of 3D bioprinting applications, including soft and hard tissues Collink.3D™ 90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2D and 3D cell culture Second bioink launch advances Company's strategic goal to build portfolio of rhCollagen-based bioinks for biopharma and academic customers REHOVOT, Israel , Nov. 7, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company is launching Collink.3D™ 90, a recombinant human collagen (rhCollagen)-based bioink for use in a variety of 3D bioprinting applications. Collink.3D™ 90 is complementary to the Company's first commercial bioink, Collink.3D™ 50, which was launched late last year, offering increased mechanical properties to address additional printing requirements of soft and hard tissues.

CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90

REHOVOT, Israel , Nov. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human-collagen based technologies and products for tissue regeneration and organ manufacturing, today announced that Eran Rotem, Collplant's Deputy CEO and Chief Financial Officer, will present a company overview at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum at the Westin NY Grand Central Hotel.  Mr.

CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

REHOVOT, Israel , Oct. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the Company's Deputy CEO & Chief Financial Officer Eran Rotem, will present a company overview at the Dawson James 7th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida. Mr.

CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

REHOVOT, Israel , Sept. 19, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company will make a presentation on "Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications" at the International Conference on Biofabrication on September 28 th.

CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

REHOVOT, Israel , Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced that Deputy CEO and CFO Eran Rotem will participate in investor conferences later this month.

CollPlant Biotechnologies to Participate in September Investor Conferences

Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing Company's 3D bioprinted regenerative breast implant program remains on track to conclude large animal study in Q4 Development of aseptic process for the production of sterile rhCollagen anticipated to be completed in Q4 Strong balance sheet with cash and cash equivalents of $36M as of June 30, 2022 REHOVOT, Israel , Aug. 25, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2022 and provided an update on the Company's business developments. "I am very pleased with the company's execution and significant advances across our diverse and expanding product portfolio.

CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results

At the Tissue Engineering and Regenerative Medicine International Society conference, CollPlant will deliver a presentation 'rhCollagen - The Ideal Building Block For 3D Printed and Injectable Scaffolds for Regenerative Medicine' and a poster 'Recombinant Human Collagen-Based Bioinks for Biofabrication Applications' REHOVOT, Israel , July 5, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the company will deliver two presentations, and will have an exhibition booth at the annual conference and exhibition of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), in Toronto, Canada, on July 10-13, 2022. "We look forward to participating at the TERMIS conference, a leading organization in the field of tissue engineering and regenerative medicine," said Yehiel Tal, CollPlant's Chief Executive Officer.

CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada

rhCollagen-based regenerative breast implants address $2.8 billion global breast implant market with revolutionary and potentially safer new product Regenerative breast implants for aesthetic and reconstructive procedures including postmastectomy for cancer patients The study is planned to be concluded within six months REHOVOT, Israel , June 28, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market. "This study is a quantum leap in the development of 3D bioprinted regenerative breast implants," said Yehiel Tal, CollPlant's Chief Executive Officer.

CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study

Co-development of rhCollagen-based dermal and soft tissue filler products with AbbVie is advancing according to plan Launch of large animal study for Company's 3D bioprinted regenerative breast implant program is on track for Q2 2022 Initiate development of a 3D bioprinted tissue model of the human intestine to support drug discovery and personalized medicine for inflammatory bowel diseases in Q3 2022 Reports strong balance sheet with cash and cash equivalents of $41M as of March 31, 2022 REHOVOT, Israel , May 26, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the first quarter ended March 31, 2022. "CollPlant continues to make important progress executing our internal pipeline and partnered programs, including our strategic agreement with AbbVie to co-develop dermal and soft fillers using our proprietary collagen technology.

News for CollPlant Biotechnologies Ltd - ADR Stock (CLGN)